Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Leflunomide - sanofi-aventis

Drug Profile

Leflunomide - sanofi-aventis

Alternative Names: Arava; HWA 486; SU 101

Latest Information Update: 18 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer Pfizer
  • Class Antineoplastics; Disease-modifying antirheumatics; Isoxazoles; Small molecules
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors; Dihydropteroate synthase inhibitors; Epidermal growth factor receptor antagonists; Immunosuppressants; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Psoriatic arthritis; Rheumatoid arthritis
  • Discontinued Anaplastic astrocytoma; Autoimmune disorders; Cytomegalovirus infections; Glioblastoma; Graft-versus-host disease; Hypersensitivity; Immune-mediated uveitis; Multiple sclerosis; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Psoriasis; Systemic lupus erythematosus; Transplant rejection

Most Recent Events

  • 03 Dec 2018 Chang Zheng-Cinkate Pharmaceutical Corporation terminates a phase II trial for the prevention of kidney Transplant rejection in the USA due to lack of recruitment (PO) (NCT01620268)
  • 24 Jun 2018 Biomarkers information updated
  • 01 Oct 2015 Generic equivalent available in USA for Rheumatoid arthritis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top